AgingResearch.NewsJoin free
Lancet

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

By Jacqueline A. French, John A. Lawson, Zühal Yapıcı, Show 10 more authorsDavid Neal Franz
Randomised trial in 366 peopleInterventions

Double-blind, placebo-controlled, multicentre, registered NCT01713946

Paper

The paper

Jacqueline A. French, John A. Lawson, Zühal Yapıcı, Show 10 more authorsDavid Neal Franz

NYU Langone Health; Cincinnati Children's Hospital Medical Center

Lancet, 6 Sep 2016

doi.org/10.1016/s0140-6736(16)31419-2PubMed 27613521

More on mTOR signalling